ArticlePediatric surgery international2026
Hypoxia-conditioned umbilical cord mesenchymal stem cell secretome attenuates hepatic fibrosis in a bile duct ligation model of biliary atresia.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBiliary atresia (BA) is a progressive fibro-inflammatory cholangiopathy and the leading cause of neonatal cholestasis and pediatric liver transplantation. Mesenchymal stem cell (MSC)-derived secretome has emerged as promising acellular alternative to cell therapy. This study evaluated the potential of hypoxia-conditioned umbilical cord MSC (HU-UCMSC) secretome in rat model of biliary fibrosis induced by bile duct ligation (BDL).
methodsTwenty-four male Sprague-Dawley rats were randomized into six groups: Sham, BDL, BDL + vehicle, and BDL treated with HU-UCMSC secretome at doses of 100, 200, and 400 μL. Serum biochemical markers and hepatic gene expression were analyzed using photometry and RT-qPCR. Histopathology and fibrosis fraction area were evaluated by Sirius Red staining.
resultsHU-UCMSC secretome produced dose-dependent hepatoprotection, significantly reducing SGOT, SGPT, and total bilirubin levels compared with untreated BDL rats. Histologically, collagen deposition and fibrosis fraction area were markedly reduced. Gene expression analysis showed significant downregulation of PDGF, α-SMA, and TNF-α, with context-dependent modulation of TGF-β and VEGF.
conclusionHypoxia-conditioned UC-MSC secretome improved hepatic function and mitigated fibrosis in the BDL model through suppression of profibrotic and inflammatory mediators. These findings support HU-UCMSC secretome as a safe, cell-free therapeutic candidate for biliary atresia and related pediatric cholestatic liver diseases.
Indexed as
Identifiers
41758387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.